Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) EBIT Margin (2022 - 2025)

Stoke Therapeutics has reported EBIT Margin over the past 4 years, most recently at 4382.24% for Q4 2025.

  • Quarterly results put EBIT Margin at 4382.24% for Q4 2025, down 432187.0% from a year ago — trailing twelve months through Dec 2025 was 11.16% (up 26614.0% YoY), and the annual figure for FY2025 was 11.16%, up 26615.0%.
  • EBIT Margin for Q4 2025 was 4382.24% at Stoke Therapeutics, down from 405.3% in the prior quarter.
  • Over the last five years, EBIT Margin for STOK hit a ceiling of 70.15% in Q1 2025 and a floor of 4382.24% in Q4 2025.
  • Median EBIT Margin over the past 4 years was 727.04% (2022), compared with a mean of 871.34%.
  • Biggest five-year swings in EBIT Margin: surged 99551bps in 2024 and later plummeted -432187bps in 2025.
  • Stoke Therapeutics' EBIT Margin stood at 831.58% in 2022, then fell by -27bps to 1055.89% in 2023, then soared by 94bps to 60.37% in 2024, then tumbled by -7158bps to 4382.24% in 2025.
  • The last three reported values for EBIT Margin were 4382.24% (Q4 2025), 405.3% (Q3 2025), and 197.58% (Q2 2025) per Business Quant data.